Pharmacogenomics in Europe: How Your DNA Affects Which Drugs Work For You

Every year, adverse drug reactions (ADRs) account for roughly 197,000 deaths across the European Union and cost healthcare systems an estimated 79 billion euros. A significant fraction of these reactions are preventable -- because they stem not from prescribing errors or allergies, but from genetic variation in how individual patients metabolize medications.

This is the domain of pharmacogenomics (PGx): the study of how your DNA influences your response to drugs. It is one of the most clinically actionable areas of genomics today, and Europe is at the forefront of integrating it into routine healthcare.

What Is Pharmacogenomics?

When you take a medication, your body must absorb it, distribute it to the right tissues, metabolize it (often in the liver), and eventually eliminate it. At nearly every step, enzymes encoded by your genes do the heavy lifting. Variation in those genes -- different alleles inherited from your parents -- can make these enzymes work faster, slower, or not at all.

The result: the same dose of the same drug can be therapeutic for one person, ineffective for another, and dangerously toxic for a third. Pharmacogenomics identifies these genetic differences and translates them into concrete prescribing guidance -- which drug to choose, and at what dose.

This is not theoretical medicine. Clinical guidelines already exist for over 100 drug-gene interactions, and the evidence base grows every year.

The Key Genes: A Practical Overview

Five gene families account for the majority of clinically actionable pharmacogenomic interactions. Understanding them is the foundation of PGx literacy.

CYP2D6: The Most Polymorphic Drug-Metabolizing Enzyme

CYP2D6 metabolizes approximately 25% of all commonly prescribed drugs, including codeine, tramadol, tamoxifen, and many antidepressants (venlafaxine, nortriptyline, paroxetine). It is also one of the most genetically variable enzymes in the human body, with over 130 known allelic variants and significant differences in allele frequency across populations.

Why it matters clinically: Codeine is a prodrug -- it does nothing until CYP2D6 converts it into morphine. Poor metabolizers get no pain relief from codeine. Ultra-rapid metabolizers convert codeine to morphine so efficiently that standard doses can cause respiratory depression, which has proven fatal in children and breastfeeding infants. The FDA now carries a black box warning on codeine for this reason.

For antidepressants metabolized by CYP2D6, poor metabolizers accumulate the drug at dangerously high plasma concentrations on standard doses, leading to severe side effects. Ultra-rapid metabolizers clear the drug too quickly and experience treatment failure.

CYP2C19: Clopidogrel, PPIs, and SSRIs

CYP2C19 is critical for activating clopidogrel (Plavix), the antiplatelet drug prescribed to millions of patients after cardiac stenting. Clopidogrel is another prodrug: poor metabolizers cannot activate it effectively, leaving them at significantly elevated risk of stent thrombosis -- a potentially fatal event.

The FDA added a boxed warning to clopidogrel in 2010 recommending consideration of alternative therapies for CYP2C19 poor metabolizers. Yet most patients still receive clopidogrel without any genetic testing.

CYP2C19 also metabolizes proton pump inhibitors (omeprazole, lansoprazole) and several SSRIs (escitalopram, sertraline). Rapid metabolizers may need higher PPI doses to control acid reflux, while poor metabolizers may experience excessive drug exposure on standard SSRI doses.

CYP2C9 and VKORC1: The Warfarin Story

Warfarin remains one of the most widely prescribed anticoagulants in the world, and it has one of the narrowest therapeutic windows of any drug. Too little, and patients form life-threatening clots. Too much, and they hemorrhage.

Two genes dominate warfarin pharmacogenomics. CYP2C9 metabolizes the more potent S-enantiomer of warfarin; variants like CYP2C9*2 and *3 reduce enzyme activity, causing the drug to accumulate. VKORC1 encodes the molecular target of warfarin; common variants alter sensitivity to the drug at the receptor level.

Together, CYP2C9 and VKORC1 genotypes explain roughly 40% of the variability in warfarin dose requirements -- far more than any clinical factor alone. Genotype-guided dosing algorithms have been validated in randomized controlled trials and are recommended by CPIC guidelines.

DPYD: When Chemotherapy Becomes Life-Threatening

Dihydropyrimidine dehydrogenase, encoded by the DPYD gene, is responsible for breaking down fluoropyrimidine chemotherapy agents -- 5-fluorouracil (5-FU) and its oral prodrug capecitabine. These are among the most commonly used chemotherapies worldwide, prescribed for colorectal, breast, head and neck, and gastric cancers.

Approximately 3-8% of the European population carries a partial DPYD deficiency, and roughly 0.1-0.5% are fully deficient. For these patients, standard fluoropyrimidine doses cause catastrophic toxicity: severe mucositis, myelosuppression, and in some cases, death. The European Medicines Agency (EMA) now recommends DPYD testing before prescribing fluoropyrimidines, and several European countries have made it mandatory.

This is pharmacogenomics at its most urgent. A simple genetic test costing under 200 euros can prevent a fatal drug reaction.

TPMT and NUDT15: Thiopurine Toxicity

TPMT (thiopurine S-methyltransferase) and NUDT15 metabolize thiopurine drugs -- azathioprine, mercaptopurine, and thioguanine -- used to treat autoimmune conditions, inflammatory bowel disease, and acute lymphoblastic leukemia. Patients with reduced TPMT or NUDT15 activity accumulate toxic thioguanine nucleotides, leading to severe and potentially fatal myelosuppression.

CPIC guidelines recommend genotyping both TPMT and NUDT15 before initiating thiopurine therapy, with dose reductions of 50-90% for intermediate and poor metabolizers respectively.

Metabolizer Phenotypes: The Classification System

Pharmacogenomics assigns each patient a metabolizer phenotype based on their genotype for a given enzyme. The standard classification includes five categories:

• Poor Metabolizer (PM): Little to no functional enzyme activity. Prodrugs are not activated; active drugs accumulate to toxic levels.
• Intermediate Metabolizer (IM): Reduced enzyme activity. Dose reductions are often needed.
• Normal Metabolizer (NM): Typical enzyme activity. Standard dosing applies. (Previously called "extensive metabolizer.")
• Rapid Metabolizer (RM): Above-average enzyme activity. Some drugs are cleared faster than expected.
• Ultra-Rapid Metabolizer (UM): Substantially increased enzyme activity, often due to gene duplication. Prodrugs may cause toxicity from excessive activation; active drugs may be ineffective.

The clinical significance of each phenotype depends entirely on the specific drug. Being a CYP2D6 ultra-rapid metabolizer is dangerous with codeine but may be clinically irrelevant for other medications.

Real Clinical Impact: Cases That PGx Testing Could Have Prevented

The clinical case literature is sobering. A few representative examples illustrate why pharmacogenomics is not an academic exercise:

Case 1: Fatal codeine toxicity in a breastfeeding infant. A mother prescribed codeine after cesarean delivery was a CYP2D6 ultra-rapid metabolizer. Morphine accumulated in her breast milk at concentrations high enough to cause neonatal opioid toxicity. The infant died at 13 days of age. A CYP2D6 test would have flagged the risk and prompted an alternative analgesic.

Case 2: Stent thrombosis on clopidogrel. A 58-year-old man received a coronary stent and was prescribed clopidogrel. As a CYP2C19 poor metabolizer, he could not activate the drug. He suffered stent thrombosis six weeks later, resulting in a myocardial infarction. Ticagrelor or prasugrel -- alternatives that do not depend on CYP2C19 -- would have been appropriate.

Case 3: Fatal fluoropyrimidine toxicity. A colorectal cancer patient received standard-dose capecitabine without DPYD testing. She carried the DPYD*2A variant (complete loss of one allele). She developed grade 4 neutropenia and mucositis and died of sepsis. Pre-treatment DPYD genotyping would have indicated a 50% dose reduction.

These are not rare edge cases. They represent systematic, predictable, and preventable harm.

CPIC Guidelines: The Evidence Standard

The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, evidence-based guidelines that translate genotype results into specific prescribing recommendations. Each guideline undergoes rigorous systematic review and assigns a level of evidence to each drug-gene interaction.

CPIC guidelines currently cover over 25 genes and nearly 100 drug-gene pairs. They are freely available at cpicpgx.org and are designed for direct clinical implementation -- they tell prescribers exactly what to do when a patient's genotype is known.

Critically, CPIC guidelines address a common misconception: they do not recommend whether to test. They assume the genotype is already available and provide guidance on how to use it. This "test-agnostic" approach means the guidelines are equally applicable whether the genotype came from a dedicated PGx panel, whole-genome sequencing, or reanalysis of existing consumer genomics data.

Europe Leading the Way

While pharmacogenomics implementation has been uneven globally, several European countries are pioneering systematic integration of PGx into clinical care.

The Netherlands: DPWG and Pre-Emptive Testing

The Dutch Pharmacogenetics Working Group (DPWG) has been publishing pharmacogenomics guidelines since 2005, and the Netherlands is arguably the world leader in clinical PGx implementation. Dutch guidelines are integrated directly into electronic prescribing systems: when a pharmacist dispenses a medication, the system automatically checks whether a relevant genotype is on file and generates an alert with dosing recommendations.

The PREPARE study, a landmark European randomized controlled trial across seven countries, demonstrated that pre-emptive PGx panel testing -- genotyping a panel of pharmacogenes before any specific drug is prescribed -- reduced adverse drug reactions by 30%. This "test once, use many times" model is the future of pharmacogenomics.

United Kingdom: NHS Pharmacogenomics Pilot

NHS England has launched pharmacogenomics pilot programs through the National Genomic Medicine Service, exploring how PGx testing can be integrated into primary care and oncology pathways. The UK Pharmacogenomics Clinical Implementation Group is developing clinical decision support tools and working to establish PGx testing as a standard component of the NHS Long Term Plan.

The UK Biobank, with genetic and health data from 500,000 participants, has also become an invaluable resource for pharmacogenomics research, enabling large-scale studies of drug-gene interactions in real-world populations.

The EU 1+ Million Genomes Initiative

The 1+ Million Genomes Initiative (1+MG), signed by 25 EU member states, aims to create cross-border access to genomic data for research and clinical care. Pharmacogenomics is one of the initiative's priority use cases, with the explicit goal of enabling PGx-guided prescribing across European healthcare systems.

This initiative addresses one of the key barriers to PGx adoption: interoperability. By establishing common standards for genomic data, 1+MG makes it possible for a PGx profile generated in one country to be used by a prescriber in another.

Getting Your PGx Profile from Existing Data

If you have already taken a consumer genomics test from 23andMe, AncestryDNA, or a similar provider, you may already have data relevant to pharmacogenomics. These services genotype hundreds of thousands of SNPs across the genome, and many of the key pharmacogenomic variants are included on their arrays.

By downloading your raw data file and uploading it to an analysis platform like DeepDNA, you can extract pharmacogenomic insights from data you have already paid for. Our analysis maps your genotyped variants to established star allele nomenclature and applies CPIC guidelines to generate actionable reports. If you are unsure how to obtain your raw data, our complete guide to using your 23andMe raw data walks through the process step by step.

Important Limitations: What SNP Arrays Cannot Detect

Transparency about limitations is essential. Consumer genotyping arrays (including those from 23andMe and Ancestry) have important blind spots for pharmacogenomics:

Structural variants and copy number variation. CYP2D6 is notorious for gene deletions, duplications, and hybrid gene arrangements. SNP arrays cannot reliably detect CYP2D6 gene copy number, which means they may miss ultra-rapid metabolizers (who carry extra gene copies) and some poor metabolizers (who carry whole-gene deletions). This is clinically significant.

Rare and novel variants. SNP arrays test for a predefined set of known variants. If you carry a rare or population-specific allele that is not on the array, it will not be detected. Your result will default to the reference allele, potentially assigning you a "normal metabolizer" phenotype when your true phenotype is different.

Star allele assignment complexity. Translating raw SNP data into star alleles (the nomenclature system used by CPIC) requires sophisticated phasing algorithms, especially for genes like CYP2D6 where the relationship between SNPs and function is complex.

For these reasons, a PGx report derived from a consumer SNP array should be considered a useful screening tool, not a definitive clinical-grade result. When a clinically significant finding is identified, confirmatory testing through a certified laboratory may be warranted, particularly before making high-stakes prescribing decisions.

How DeepDNA Provides Pharmacogenomics Analysis

DeepDNA analyzes your existing raw genotype data against CPIC guidelines to generate a comprehensive pharmacogenomics report. Our analysis covers the major pharmacogenes discussed in this article -- CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, TPMT, NUDT15, and others -- and translates your genotype into metabolizer phenotypes with corresponding drug recommendations.

We are transparent about confidence levels. When a star allele call is well-supported by the available SNP data, we report it with high confidence. When structural variation or phasing ambiguity limits certainty, we flag it clearly and recommend confirmatory testing.

Our reports also cover related areas of genomic health. Variants in the MTHFR gene, for example, affect folate metabolism and can interact with methotrexate response -- an intersection of nutrigenomics and pharmacogenomics that many services overlook.

All analysis is performed in compliance with European data protection regulations. Your genetic data is processed under the strict standards required by GDPR, which you can read more about in our guide to GDPR and genetic data privacy.

The Path Forward

Pharmacogenomics is not a promise for the future -- it is a clinical reality today. The evidence base is strong, the guidelines are mature, and the technology is accessible. What remains is implementation: getting the right test to the right patient at the right time.

Europe's pre-emptive testing programs, regulatory mandates for DPYD genotyping, and cross-border genomic data initiatives represent the most ambitious pharmacogenomics implementation efforts anywhere in the world. As these programs scale, the question will shift from "should we test?" to "why haven't we tested yet?"

Your genome does not change. A pharmacogenomics profile generated today will remain relevant for every prescription you receive for the rest of your life. Whether you are starting a new medication, managing a chronic condition, or simply want to be prepared, understanding how your genes affect your drug response is one of the most practical steps you can take with your genetic data.

DeepDNA provides pharmacogenomics analysis based on CPIC guidelines using your existing 23andMe or AncestryDNA raw data. Upload your data to receive your personalized PGx report today.